Jones Financial Companies Lllp Boosts Stake in Solventum Corporation $SOLV

Key Points

• Jones Financial Companies Lllp significantly increased its holdings in Solventum Corporation by 3,484.6% during the first quarter, now owning approximately 120,656 shares valued at $9.18 million.
• Several large investors, including Rossby Financial and Strengthening Families & Communities, also made substantial changes to their positions in Solventum during the first quarter.
• Recent analyst reports have favorably impacted SOLV's stock, with price targets raised by firms like Morgan Stanley and Wells Fargo, reflecting a growing optimism about the company.

Jones Financial Companies Lllp grew its position in Solventum Corporation (NYSE:SOLV - Free Report) by 3,484.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,656 shares of the company's stock after buying an additional 117,290 shares during the quarter. Jones Financial Companies Lllp owned 0.07% of Solventum worth $9,175,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Trian Fund Management L.P. raised its holdings in shares of Solventum by 18.8% in the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock valued at $559,054,000 after buying an additional 1,336,564 shares during the period. Independent Franchise Partners LLP raised its holdings in shares of Solventum by 263.1% in the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock valued at $442,608,000 after buying an additional 4,217,570 shares during the period. Davis Selected Advisers raised its holdings in shares of Solventum by 0.8% in the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock valued at $402,110,000 after buying an additional 41,524 shares during the period. Boston Partners raised its holdings in shares of Solventum by 101.3% in the 1st quarter. Boston Partners now owns 3,361,973 shares of the company's stock valued at $255,554,000 after buying an additional 1,691,565 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Solventum by 3.3% in the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock valued at $137,456,000 after buying an additional 58,373 shares during the period.

Solventum Stock Down 0.6%

Shares of NYSE:SOLV traded down $0.47 on Friday, hitting $73.32. 1,572,374 shares of the company's stock were exchanged, compared to its average volume of 1,005,564. The firm's 50-day moving average is $73.09 and its 200 day moving average is $72.50. The company has a market capitalization of $12.71 billion, a PE ratio of 33.95, a P/E/G ratio of 2.99 and a beta of 0.53. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SOLV. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a report on Tuesday, July 1st. Piper Sandler reiterated an "overweight" rating and issued a $94.00 price objective (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Morgan Stanley raised Solventum from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. Wells Fargo & Company boosted their target price on Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Finally, Wall Street Zen cut Solventum from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Solventum has an average rating of "Hold" and a consensus price target of $85.11.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.